Trial Profile
A Phase II Trial of MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Monalizumab (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms MOZART
- Sponsors AstraZeneca
- 11 Aug 2023 Planned initiation date changed from 30 Jul 2023 to 1 Aug 2023.
- 18 Jul 2023 Planned initiation date changed from 30 Jun 2023 to 30 Jul 2023.
- 06 Jul 2023 Status changed from not yet recruiting to recruiting.